Not applicableApproved For MarketingNCT05232110What this trial is testingCompassionate Use of PozelimabWho this might be right forCD55-deficient Protein-losing Enteropathy Regeneron Pharmaceuticals
Large-scale testing (Phase 3)Study completedNCT04209634What this trial is testingOpen-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)Who this might be right forCD55-deficient Protein-losing EnteropathyCHAPLE Regeneron Pharmaceuticals 10
Post-approval studies (Phase 4)Looking for participantsNCT07142343What this trial is testingTest the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) DiseaseWho this might be right forCHAPLE Disease Regeneron Pharmaceuticals 5
Not applicableUnknownNCT03950804What this trial is testingTranscriptome and Metabolic Analyses of CHAPLE DiseaseWho this might be right forCD55 - Cluster of Differentiation Antigen 55 DeficiencyPrimary Intestinal LymphangiectasisProtein-Losing Enteropathies+1 more Marmara University 60
Not applicableApproved For MarketingNCT06003881What this trial is testingCompassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing EnteropathyWho this might be right forCD55-Deficient Protein-Losing Enteropathy Regeneron Pharmaceuticals